Brain and behavior correlates of prenatal cannabis exposure

产前大麻暴露的大脑和行为相关性

• 批准号: 10734717
• 负责人: STEPHEN R DAGER
• 金额: $ 69.61万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-15 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10734717
• 关键词: ATOD; Affect; Age; Age Months; Alcohols; Amygdaloid structure; Animal Experimentation; Animals; Antiemetics; Anxiety; Attention; Behavior; Behavioral; Binding; Biological Assay; Birth; Birth Weight; Brain; Brain imaging; Brain region; COVID-19 pandemic; Cannabidiol; Cannabinoids; Cannabis; Cell Adhesion Molecules; Cerebellum; Complementary and alternative medicine; Conceptions; Conscious; Consumption; Data; Development; Diffusion Magnetic Resonance Imaging; Disease; Dopamine D2 Receptor; Dose; Early Diagnosis; Educational Status; Endocannabinoids; Enrollment; Evaluation; Exclusion Criteria; Exhibits; Female; First Pregnancy Trimester; Frequencies; Functional Magnetic Resonance Imaging; Goals; Growth; Head circumference; Health; Health Benefit; Human; Illicit Drugs; Infant; Influentials; Label; Legal; Legal Status; Length; Magnetic Resonance Imaging; Measures; Medicine; Memory; Modernization; Monitor; Mothers; Multimodal Imaging; Nausea and Vomiting; Neonatal; Neurodevelopmental Disorder; Neuropsychology; Newborn Infant; Odors; Outcome; Outcomes Research; Pacific Northwest; Participant; Pathway interactions; Patient Self-Report; Perception; Persons; Pharmacologic Substance; Placenta; Population; Pregnancy; Pregnant Women; Product Labeling; Property; Prospective Studies; Protocols documentation; Psychotropic Drugs; Recreation; Regulation; Reporting; Research; Risk; Second Pregnancy Trimester; Sex Differences; Signal Transduction; Sleep; Stimulus; Structure; System; Testing; Tetrahydrocannabinol; Third Pregnancy Trimester; Time; Tobacco; Update; Urine; Visit; Washington; Woman; Work; adverse outcome; autism spectrum disorder; behavior measurement; behavioral outcome; brain dysfunction; cannabinoid receptor; density; design; drug of abuse; experience; fetal marijuana exposure; follow up assessment; frontal lobe; imaging study; in utero; indexing; infancy; infant outcome; innovation; male; marijuana legalization; marijuana use; marijuana use in pregnancy; marijuana user; maternal marijuana use; motor behavior; myelination; neural; neurobehavior; neurobehavioral; neurodevelopment; pain reduction; polysubstance use; pregnant; prenatal; prenatal exposure; programs; prospective; receptor density; recruit; response; reward processing; symptom management; white matter

Cannabis use during pregnancy has increased substantially, in conjunction with widespread decriminalization/legalization, changing public perceptions about harm, and evidence of cannabis's antiemetic properties. Prior outcomes research on prenatal cannabis exposure is narrow in scope, as these older studies included research participants with polysubstance use (e.g., tobacco, alcohol, illicit drugs). In addition, prior research also likely underestimated potential risks specific to cannabis use during pregnancy because modern strains are 10x more potent than they were 40 years ago. We propose to study neurodevelopment in infants exposed in utero to cannabis using state-of-the-art MRI and behavioral measures. Maternal cannabis use will be measured prospectively using weekly reports validated with labels and urine-based assays. By focusing on infancy, we aim to characterize cannabis-induced brain changes at a time when environmental effects are minimized and are less influential than at older. In addition, we will test the hypothesis that prenatal cannabis exposure is more detrimental to male than females. To test our hypotheses, we will recruit 200 pregnant people (where the mother uses cannabis, but not other drugs, tobacco, or alcohol) and 170 pregnant control participants matched on education level. Infants will receive a neonatal neurobehavioral exam and multi-modal imaging (functional magnetic resonance imaging, diffusion tensor imaging, and structural MRI) under natural sleep at 2-4 weeks-of-age and extensive neuropsychological follow-up assessments at 6 and 18 months. This program of research aims to clarify potential health risks, enabling pregnant people to make better-informed choices surrounding cannabis use during pregnancy.

怀孕期间大麻的使用大幅增加，同时广泛传播 非刑事化/合法化、改变公众对危害的看法以及大麻止吐的证据 特性。先前关于产前大麻暴露的结果研究范围狭窄，因为这些较旧的研究 包括使用多种物质（例如烟草、酒精、非法药物）的研究参与者。另外，之前 研究还可能低估了怀孕期间使用大麻的潜在风险，因为现代 菌株的效力比 40 年前强 10 倍。我们建议研究婴儿的神经发育 使用最先进的 MRI 和行为测量在子宫内暴露于大麻。产妇吸食大麻会 使用经标签和尿液检测验证的每周报告进行前瞻性测量。通过专注于 在婴儿期，我们的目标是在环境影响严重的时候描述大麻引起的大脑变化的特征 与年长时相比，其影响力已最小化且较小。此外，我们将检验产前大麻的假设 暴露对男性的危害比女性更大。为了检验我们的假设，我们将招募 200 名孕妇 人（母亲使用大麻，但不使用其他药物、烟草或酒精）和 170 名怀孕对照 参与者的教育水平相匹配。婴儿将接受新生儿神经行为检查和多模式检查 自然条件下的成像（功能磁共振成像、扩散张量成像、结构磁共振成像） 2-4 周龄时进行睡眠，并在 6 个月和 18 个月时进行广泛的神经心理学随访评估。这 该研究计划旨在澄清潜在的健康风险，使孕妇能够更好地了解情况 关于怀孕期间使用大麻的选择。